{{Short description|Experimental muscarinic drug}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox drug | drug_name = | image = | width = | caption =
<!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = Oral<ref name="AdisInsight" /> | class = Muscarinic acetylcholine M<sub>4</sub> receptor positive allosteric modulator<ref name="AdisInsight" /><ref name="YohnHarveyBrannan2024" /> | ATC_prefix = | ATC_suffix =
<!-- Legal status --> | legal_status =
<!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion =
<!-- Identifiers --> | CAS_number = | CAS_supplemental = | PubChem = | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = NS136
<!-- Chemical data --> | IUPAC_name = | C= | H= | N= | O= | SMILES = | StdInChI = | StdInChIKey = }}
'''NS-136''' is a selective muscarinic acetylcholine M<sub>4</sub> receptor positive allosteric modulator which is under development for the treatment of schizophrenia and Alzheimer's disease.<ref name="AdisInsight">{{cite web | title=NS 136 | work = AdisInsight | publisher = Springer Nature Switzerland AG | date=15 May 2024 | url=https://adisinsight.springer.com/drugs/800075213 | access-date=21 October 2024}}</ref><ref name="Synapse">{{cite web | title=Delving into the Latest Updates on NS-136 with Synapse | website=Synapse | date=19 September 2024 | url=https://synapse.patsnap.com/drug/656aaf00a11f4888a7bb37436f132450 | access-date=21 October 2024}}</ref><ref name="YohnHarveyBrannan2024">{{cite journal | vauthors = Yohn SE, Harvey PD, Brannan SK, Horan WP | title=The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia | journal=Frontiers in Psychiatry | publisher=Frontiers Media SA | volume=15 | date=4 October 2024 | issn=1664-0640 | doi=10.3389/fpsyt.2024.1421554 | doi-access=free | page=| pmid=39483736 | pmc=11525114 }}</ref> It has been found to possess pro-cognitive effects in rodents.<ref name="YohnHarveyBrannan2024" /> The drug is under development by NeuShen Therapeutics.<ref name="AdisInsight" /><ref name="Synapse" /> As of May 2024, it is in phase 1 clinical trials for schizophrenia and is in the preclinical stage of development for Alzheimer's disease.<ref name="AdisInsight" /><ref name="Synapse" /> The drug is a small molecule, but its chemical structure does not seem to have been disclosed.<ref name="AdisInsight" /><ref name="Synapse" />
==See also== * Emraclidine * NBI-1117568 * Xanomeline
==References== {{Reflist}}
{{Muscarinic acetylcholine receptor modulators}}
Category:Drugs with undisclosed chemical structures Category:Experimental drugs for Alzheimer's disease Category:Experimental drugs developed for schizophrenia Category:M4 receptor positive allosteric modulators
{{Pharma-stub}}